Drug Trial Radar · NCT07728383
A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity
Last checked: Nov 20, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Jun 17, 2026
Primary completion
May 2027
Study completion May 2027
Sponsor
- Lead sponsor
- Gila Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study investigates the Topical-Lingual (T-L) delivery of semaglutide, a GLP-1 receptor agonist (GLP-1RA), via an oral liquid emulsion formulation as a Proof-of-Concept for the T-L delivery of metabolic hormones in general. GLP-1 is a gut-derived hormone that induces satiation through hypothalamic pathways.
Conditions
- Obesity & Overweight
Interventions
Semaglutide 6 mg liquid emulsion formulationDrug
Semaglutide 6 mg liquid emulsion formulation daily
Wegovy® (semaglutide) TabletDrug
Wegovy® (semaglutide) Tablet 25 mg daily
Placebo liquid emulsion formulationDrug
Placebo liquid emulsion formulation daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent body weight change from baselineTime frame: 24 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical Research Institute of Minnesota
Minneapolis, Minnesota · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.